BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79. [PMID: 30231359 DOI: 10.1200/EDBK_200939] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Yue C, Liang C, Ge H, Yan L, Xu Y, Li G, Wu J. SUCO as a Promising Diagnostic Biomarker of Hepatocellular Carcinoma: Integrated Analysis and Experimental Validation. Med Sci Monit 2019;25:6292-303. [PMID: 31434866 DOI: 10.12659/MSM.915262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Li X, Wu S, Yu Y. Aspirin Use and the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies. Front Med (Lausanne) 2020;7:569759. [PMID: 33490093 DOI: 10.3389/fmed.2020.569759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Huang XF, Chang KF, Lee SC, Sheu GT, Li CY, Weng JC, Hsiao CY, Tsai NM. Extract Derived from Cedrus atlantica Acts as an Antitumor Agent on Hepatocellular Carcinoma Growth In Vitro and In Vivo. Molecules 2020;25:E4608. [PMID: 33050385 DOI: 10.3390/molecules25204608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Zhao L, Yang Q, Liu J. Clinical Value Evaluation of microRNA-324-3p and Other Available Biomarkers in Patients With HBV Infection-Related Hepatocellular Carcinoma. Open Forum Infect Dis 2021;8:ofab108. [PMID: 34189151 DOI: 10.1093/ofid/ofab108] [Reference Citation Analysis]
5 Li M, Ren ZG, Cui JF. Advances in understanding of mechanism of anti-hepatocellular carcinoma effects of curcumin. Shijie Huaren Xiaohua Zazhi 2019; 27(17): 1043-1049 [DOI: 10.11569/wcjd.v27.i17.1043] [Reference Citation Analysis]
6 Mak LY, Hui RW, Fung J, Liu F, Wong DK, Li B, Cheung KS, Yuen MF, Seto WK. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int 2021;15:901-11. [PMID: 34152534 DOI: 10.1007/s12072-021-10218-2] [Reference Citation Analysis]
7 Jacobs NR, Norton PA. Role of chromosome 1q copy number variation in hepatocellular carcinoma. World J Hepatol 2021; 13(6): 662-672 [PMID: 34239701 DOI: 10.4254/wjh.v13.i6.662] [Reference Citation Analysis]
8 Li X, Liu L, Hu Y. Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis. Biosci Rep 2020;40:BSR20200232. [PMID: 32162652 DOI: 10.1042/BSR20200232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Reference Citation Analysis]
10 Ding Y, Sun Z, Zhang S, Han X, Li Y, Xu Q, Zhou L, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Down-regulation of small nuclear RNA (snRNA) RNU5E-1 in hepatocellular carcinoma presents with vital clinical significance. J Gastrointest Oncol 2020;11:738-46. [PMID: 32953157 DOI: 10.21037/jgo-20-49] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Liu R, Li Y, Wu A, Kong M, Ding W, Hu Z, Chen L, Cai W, Wang F. Identification of Plasma hsa_circ_0005397 and Combined With Serum AFP, AFP-L3 as Potential Biomarkers for Hepatocellular Carcinoma. Front Pharmacol 2021;12:639963. [PMID: 33679420 DOI: 10.3389/fphar.2021.639963] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Masior Ł, Grąt M, Grąt K, Krasnodębski M, Wronka KM, Stypułkowski J, Patkowski W, Frączek M, Krawczyk M, Zieniewicz K. Importance of Intraoperative Transfusions of Packed Red Blood Cells and Fresh Frozen Plasma in Liver Transplantation for Hepatocellular Cancer. Ann Transplant 2020;25:e923665. [PMID: 33079923 DOI: 10.12659/AOT.923665] [Reference Citation Analysis]
13 Forni C, Rossi M, Borromeo I, Feriotto G, Platamone G, Tabolacci C, Mischiati C, Beninati S. Flavonoids: A Myth or a Reality for Cancer Therapy? Molecules 2021;26:3583. [PMID: 34208196 DOI: 10.3390/molecules26123583] [Reference Citation Analysis]
14 El-Kattawy AM, Algezawy O, Alfaifi MY, Noseer EA, Hawsawi YM, Alzahrani OR, Algarni A, Kahilo KA, El-Magd MA. Therapeutic potential of camel milk exosomes against HepaRG cells with potent apoptotic, anti-inflammatory, and anti-angiogenesis effects for colostrum exosomes. Biomed Pharmacother 2021;143:112220. [PMID: 34649349 DOI: 10.1016/j.biopha.2021.112220] [Reference Citation Analysis]
15 Taye BW, Clark PJ, Hartel G, Powell EE, Valery PC. Remoteness of residence predicts tumor stage, receipt of treatment, and mortality in patients with hepatocellular carcinoma. JGH Open 2021;5:754-62. [PMID: 34263069 DOI: 10.1002/jgh3.12580] [Reference Citation Analysis]
16 Ye Y, An Y, Wang M, Liu H, Guan L, Wang Z, Li W. Expression of Carboxypeptidase X M14 Family Member 2 Accelerates the Progression of Hepatocellular Carcinoma via Regulation of the gp130/JAK2/Stat1 Pathway. Cancer Manag Res 2020;12:2353-64. [PMID: 32280274 DOI: 10.2147/CMAR.S228984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Liao H, Xiong T, Peng J, Xu L, Liao M, Zhang Z, Wu Z, Yuan K, Zeng Y. Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning. Ann Surg Oncol. 2020;27:2359-2369. [PMID: 31916093 DOI: 10.1245/s10434-019-08190-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
18 Yu L, Xu H, Zhang S, Chen J, Yu Z. SDC1 promotes cisplatin resistance in hepatic carcinoma cells via PI3K-AKT pathway. Hum Cell 2020;33:721-9. [PMID: 32314115 DOI: 10.1007/s13577-020-00362-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382 [PMID: 31363465 DOI: 10.12998/wjcc.v7.i12.1367] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
20 Sun Q, Zhang X, Gong X, Hu Z, Zhang Q, He W, Chang X, Hu Z, Chen Y. Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data. Hepatol Int 2021. [PMID: 34258665 DOI: 10.1007/s12072-021-10219-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Duong LM, Cai H, Shrubsole MJ, Bailey CE, Idrees K, Shu XO. Outcomes of robotic-assisted liver surgery versus laparoscopic liver surgery for treatment of stage I hepatocellular carcinoma. Cancer 2021. [PMID: 34674225 DOI: 10.1002/cncr.33979] [Reference Citation Analysis]
22 Elghoroury EA, Abdelghaffar EE, Awadallah E, Kamel SA, Kandil D, Hassan EM, Hassan M, Kamel MM, Gomaa MM, Fathalla LA. Detection of exosomal miR-18a and miR-222 levels in Egyptian patients with hepatic cirrhosis and hepatocellular carcinoma. Int J Immunopathol Pharmacol 2022;36:3946320221097832. [PMID: 35467432 DOI: 10.1177/03946320221097832] [Reference Citation Analysis]
23 Weng S, Xu X, Li Y, Yan C, Chen J, Ye R, Zhu Y, Wen L, Hong J. Quantitative analysis of multiphase magnetic resonance images may assist prediction of histopathological grade of small hepatocellular carcinoma. Ann Transl Med 2020;8:1023. [PMID: 32953823 DOI: 10.21037/atm-20-2874] [Reference Citation Analysis]
24 Liu L, Chen A, Chen S, Song W, Yao Q, Wang P, Zhou S. CCNB2, NUSAP1 and TK1 are associated with the prognosis and progression of hepatocellular carcinoma, as revealed by co-expression analysis. Exp Ther Med 2020;19:2679-89. [PMID: 32256749 DOI: 10.3892/etm.2020.8522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Choudhury N, Quraishi SB, Atiqullah A, Khan MSI, Al Mahtab M, Akbar SM. High Prevalence of Wilson's Diseases with Low Prevalence of Kayser-Fleischer Rings among Patients with Cryptogenic Chronic Liver Diseases in Bangladesh. Euroasian J Hepatogastroenterol 2019;9:67-70. [PMID: 32117693 DOI: 10.5005/jp-journals-10018-1299] [Reference Citation Analysis]
26 Marino D, Zichi C, Audisio M, Sperti E, Di Maio M. Second-line treatment options in hepatocellular carcinoma. Drugs Context 2019;8:212577. [PMID: 31024634 DOI: 10.7573/dic.212577] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
27 Xing M, Li J, Magistri P. A New Inflammation-Related Risk Model for Predicting Hepatocellular Carcinoma Prognosis. BioMed Research International 2022;2022:1-33. [DOI: 10.1155/2022/5396128] [Reference Citation Analysis]
28 Wu A, Li Y, Kong M, Zhu B, Liu R, Bao F, Ju S, Chen L, Wang F. Upregulated hsa_circ_0005785 Facilitates Cell Growth and Metastasis of Hepatocellular Carcinoma Through the miR-578/APRIL Axis. Front Oncol 2020;10:1388. [PMID: 32974140 DOI: 10.3389/fonc.2020.01388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Jiang Z, Zhang C, Liu X, Ma X, Bian X, Xiao X, Gao R, Sun Y, Wu W, Zhao P. Dexamethasone inhibits stemness maintenance and enhances chemosensitivity of hepatocellular carcinoma stem cells by inducing deSUMOylation of HIF‑1α and Oct4. Int J Oncol 2020;57:780-90. [PMID: 32705164 DOI: 10.3892/ijo.2020.5097] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2911-21. [PMID: 34855640 DOI: 10.1097/CM9.0000000000001888] [Reference Citation Analysis]
31 Zhuo JY, Lu D, Tan WY, Zheng SS, Shen YQ, Xu X. CK19-positive Hepatocellular Carcinoma is a Characteristic Subtype. J Cancer 2020;11:5069-77. [PMID: 32742454 DOI: 10.7150/jca.44697] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
32 Geng H, Xing Y, Zhang J, Cao K, Ye M, Wang G, Liu C. Association between viral infection other than human papillomavirus and risk of esophageal carcinoma: a comprehensive meta-analysis of epidemiological studies. Arch Virol 2021. [PMID: 34636955 DOI: 10.1007/s00705-021-05268-8] [Reference Citation Analysis]
33 Wang B, Dong W, Li X. miR-145-5p Acts as a Novel Tumor Suppressor in Hepatocellular Carcinoma Through Targeting RAB18. Technol Cancer Res Treat 2019;18:1533033819850189. [PMID: 31106707 DOI: 10.1177/1533033819850189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
34 Wu L, Yang W, Zhang Y, Du X, Jin N, Chen W, Li H, Zhang S, Xie B. Elevated Serum Uric Acid is Associated With Poor Survival in Advanced HCC Patients and Febuxostat Improves Prognosis in HCC Rats. Front Pharmacol 2021;12:778890. [PMID: 34858193 DOI: 10.3389/fphar.2021.778890] [Reference Citation Analysis]
35 Li X, Sheng L, Liu L, Hu Y, Chen Y, Lou L. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis. BMC Gastroenterol 2020;20:98. [PMID: 32272891 DOI: 10.1186/s12876-020-01222-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
36 Wang M, Huang S, Chen Z, Han Z, Li K, Chen C, Wu G, Zhao Y. Development and validation of an RNA binding protein-associated prognostic model for hepatocellular carcinoma. BMC Cancer 2020;20:1136. [PMID: 33228611 DOI: 10.1186/s12885-020-07625-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Zhang C, Zhang Q, Li H, Wu Y. miR-1229-3p as a Prognostic Predictor Facilitates Cell Viability, Migration, and Invasion of Hepatocellular Carcinoma. Horm Metab Res 2021;53:759-66. [PMID: 34740278 DOI: 10.1055/a-1646-8415] [Reference Citation Analysis]
38 Burenina OY, Lazarevich NL, Kustova IF, Shavochkina DA, Moroz EA, Kudashkin NE, Patyutko YI, Metelin AV, Kim EF, Skvortsov DA, Zatsepin TS, Rubtsova MP, Dontsova OA. Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors. J Cancer Res Clin Oncol 2021;147:49-59. [PMID: 32918630 DOI: 10.1007/s00432-020-03378-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 Qayum K, Kar I, Rashid U, Nawaz G, Krishnakumar P, Sudarshan V, Syed A. Effects of surgery, chemotherapy, and radiation on hepatocellular carcinoma patients: A SEER-based study. Ann Med Surg (Lond) 2021;69:102782. [PMID: 34522376 DOI: 10.1016/j.amsu.2021.102782] [Reference Citation Analysis]
40 Wang X, Zhou Y, Dong K, Zhang H, Gong J, Wang S. Exosomal lncRNA HMMR-AS1 mediates macrophage polarization through miR-147a/ARID3A axis under hypoxia and affects the progression of hepatocellular carcinoma. Environ Toxicol 2022. [PMID: 35179300 DOI: 10.1002/tox.23489] [Reference Citation Analysis]
41 Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP, Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Hoang MTQ, Too CW, Thng CH, Chan WY, Kee W, Chan JHM, Irani F, Leong S, Lim KH, Wang MLC, Chow PKH. Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver Cancer 2021;10:224-39. [PMID: 34239809 DOI: 10.1159/000514400] [Reference Citation Analysis]
42 Huang PJ, Chiu CC, Hsiao MH, Yow JL, Tzang BS, Hsu TC. Potential of antiviral drug oseltamivir for the treatment of liver cancer. Int J Oncol 2021;59:109. [PMID: 34859259 DOI: 10.3892/ijo.2021.5289] [Reference Citation Analysis]
43 Gębska-Kuczerowska A, Lahiri S, Gajda R. Bridging the Gap between Theory, Practice, and Policy: A Decision-Making Process Based on Public Health Evidence Feasible in Multi-Stage Research on Biological Risk Factors in Poland. Int J Environ Res Public Health 2020;17:E7657. [PMID: 33092230 DOI: 10.3390/ijerph17207657] [Reference Citation Analysis]
44 Zhang Y, Zhao S, Ding H, Song X, Miao H, Cui X, Wang J, Han B. Big Data Information under Proportional Hazard Mathematical Model in Analysis of Hepatitis B Virus Infection Data of Patients with Interventional Liver Cancer through Antiviral Therapy of Entecavir. J Healthc Eng 2021;2021:6225403. [PMID: 34976330 DOI: 10.1155/2021/6225403] [Reference Citation Analysis]
45 Pathak S, Sonbol MB. Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. J Hepatocell Carcinoma 2021;8:1147-58. [PMID: 34584898 DOI: 10.2147/JHC.S268314] [Reference Citation Analysis]
46 Ju S, Wang W, Chen P, Li F, Li H, Wang M, Han X, Ren J, Duan X. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C. Clin Res Hepatol Gastroenterol 2022;:101859. [PMID: 34999249 DOI: 10.1016/j.clinre.2022.101859] [Reference Citation Analysis]
47 Xu B, Yang Q, Tang Y, Tan Z, Fu H, Peng J, Xiang X, Gan L, Deng G, Mao Q, Xu PX, Jiang Y, Ding J. SIX1/EYA1 are novel liver damage biomarkers in chronic hepatitis B and other liver diseases. Ann Transl Med 2021;9:992. [PMID: 34277792 DOI: 10.21037/atm-21-2526] [Reference Citation Analysis]
48 Giannini EG. Improving prognosis of patients with very early hepatocellular carcinoma: How far are we going? Dig Liver Dis 2021;53:143-5. [PMID: 33257141 DOI: 10.1016/j.dld.2020.11.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Ohtani N, Kawada N. Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. Hepatol Commun. 2019;3:456-470. [PMID: 30976737 DOI: 10.1002/hep4.1331] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
50 Bin X, Chen Y, Ma J, Tang R, Zhao Z, Wang K, Wang J. circ_0001588 Induces the Malignant Progression of Hepatocellular Carcinoma by Modulating miR-874/CDK4 Signaling. J Immunol Res 2021;2021:3759879. [PMID: 34722778 DOI: 10.1155/2021/3759879] [Reference Citation Analysis]
51 Nankya-Mutyoba J, Aizire J, Makumbi F, Ocama P, Kirk GD. Hepatitis B virus perceptions and health seeking behaviors among pregnant women in Uganda: implications for prevention and policy. BMC Health Serv Res 2019;19:760. [PMID: 31655575 DOI: 10.1186/s12913-019-4516-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Wu S, Liu S, Li Y, Liu C, Pan H. Lestaurtinib Has the Potential to Inhibit the Proliferation of Hepatocellular Carcinoma Uncovered by Bioinformatics Analysis and Pharmacological Experiments. Front Cell Dev Biol 2022;10:837428. [DOI: 10.3389/fcell.2022.837428] [Reference Citation Analysis]
53 Zeng H, Li L, Gao Y, Wu G, Hou Z, Liu S. Long noncoding RNA UCA1 regulates HCV replication and antiviral response via miR-145-5p/SOCS7/IFN pathway. Int J Biol Sci 2021;17:2826-40. [PMID: 34345210 DOI: 10.7150/ijbs.59227] [Reference Citation Analysis]
54 Rice DR, Dalmacy D, Hyer JM, Diaz A, Tsilimigras DI, Pawlik TM. Impact of Psychiatric Illness on Survival among Patients with Hepatocellular Carcinoma. J Gastrointest Surg 2021. [PMID: 33948863 DOI: 10.1007/s11605-021-05029-7] [Reference Citation Analysis]
55 Guo Y, Cai X, Lu H, Li Q, Zheng Y, Lin Z, Cheng Z, Yang M, Zhang L, Xiang L, Yang X. 17β-Estradiol Promotes Apoptosis of HepG2 Cells Caused by Oxidative Stress by Increasing Foxo3a Phosphorylation. Front Pharmacol 2021;12:607379. [PMID: 33790784 DOI: 10.3389/fphar.2021.607379] [Reference Citation Analysis]
56 Lorini S, Gragnani L, Zignego AL. The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis. Viruses 2020;12:E1364. [PMID: 33260407 DOI: 10.3390/v12121364] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Qiu H, Zhang G, Song B, Jia J. MicroRNA-548b inhibits proliferation and invasion of hepatocellular carcinoma cells by directly targeting specificity protein 1. Exp Ther Med 2019;18:2332-40. [PMID: 31452716 DOI: 10.3892/etm.2019.7812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
58 Letafati A, Najafi S, Mottahedi M, Karimzadeh M, Shahini A, Garousi S, Abbasi-Kolli M, Sadri Nahand J, Tamehri Zadeh SS, Hamblin MR, Rahimian N, Taghizadieh M, Mirzaei H. MicroRNA let-7 and viral infections: focus on mechanisms of action. Cell Mol Biol Lett 2022;27:14. [PMID: 35164678 DOI: 10.1186/s11658-022-00317-9] [Reference Citation Analysis]
59 Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol 2021; 27(26): 4104-4142 [PMID: 34326614 DOI: 10.3748/wjg.v27.i26.4104] [Reference Citation Analysis]
60 Khaled J, Kopsida M, Lennernäs H, Heindryckx F. Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma. Cells 2022;11:632. [DOI: 10.3390/cells11040632] [Reference Citation Analysis]
61 Shan Y, Li P. Long Intergenic Non-Protein Coding RNA 665 Regulates Viability, Apoptosis, and Autophagy via the MiR-186-5p/MAP4K3 Axis in Hepatocellular Carcinoma. Yonsei Med J. 2019;60:842-853. [PMID: 31433582 DOI: 10.3349/ymj.2019.60.9.842] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
62 Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci 2021;22:1931. [PMID: 33669204 DOI: 10.3390/ijms22041931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Wang KF, Chen YD, Mo LQ, Zhang Z, Liu YJ, Chen JX, Sui XB, Xie T, Wu SX. Integrated traditional Chinese and Western medicine in hepatocellular carcinoma treatment. Shijie Huaren Xiaohua Zazhi 2019; 27(7): 459-466 [DOI: 10.11569/wcjd.v27.i7.459] [Reference Citation Analysis]
64 Liu X, Zhao Z, Cheng Y, Tao W, Yuan C, Zhang B, Wang C. Does Chronic Kidney Disease Really Affect the Complications and Prognosis After Liver Resection for Hepatocellular Carcinoma? A Meta-Analysis. Front Surg 2022;9:870946. [DOI: 10.3389/fsurg.2022.870946] [Reference Citation Analysis]
65 Zhuang H, Ma X, Liu X, Li C, Li X, Wu L, Wen M, Shi W, Yang X. Hyaluronan-mediated motility receptor antisense RNA 1 promotes hepatitis B virus-related hepatocellular carcinoma progression by regulating miR-627-3p/High Mobility Group AT-hook 2 axis. Bioengineered 2022;13:8617-30. [PMID: 35322735 DOI: 10.1080/21655979.2022.2054151] [Reference Citation Analysis]
66 Hiraoka A, Tanizawa Y, Huang YJ, Cai Z, Sakaguchi S. Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database. Drugs Real World Outcomes 2021;8:301-14. [PMID: 33792850 DOI: 10.1007/s40801-021-00245-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Li X, Wu Y, Suo P, Liu G, Li L, Zhang X, Chen S, Xu M, Song L. Identification of a novel germline frameshift mutation p.D300fs of PMS1 in a patient with hepatocellular carcinoma: A case report and literature review. Medicine (Baltimore) 2020;99:e19076. [PMID: 32000458 DOI: 10.1097/MD.0000000000019076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]